Compare SNTI & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNTI | CNVS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8M | 54.7M |
| IPO Year | 2021 | 2016 |
| Metric | SNTI | CNVS |
|---|---|---|
| Price | $1.00 | $2.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 182.2K | 122.3K |
| Earning Date | 05-06-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.31 | ★ 108.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $78,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $84.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.13 |
| 52 Week Low | $0.77 | $1.77 |
| 52 Week High | $3.88 | $7.39 |
| Indicator | SNTI | CNVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 45.12 |
| Support Level | $0.86 | $2.31 |
| Resistance Level | $1.02 | $2.47 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 67.31 | 15.87 |
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.